Reference : Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advan...
Scientific congresses and symposiums : Paper published in a journal
Human health sciences : Oncology
http://hdl.handle.net/2268/199550
Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression
English
Verschraegen, C. []
Chen, F.L. []
Spigel, D.R. []
Iannotti, N. []
McClay, E. []
Redfern, C.H. []
Bennouna, J. []
Taylor, M. []
Kaufman, H. []
Kelly, K. []
Bajars, M. []
von Heydebreck, A. []
Cuillerot, J-M. []
JERUSALEM, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale >]
2016
Journal of Clinical Oncology
American Society of Clinical Oncology
34
abstract 9036
Yes (verified by ORBi)
International
0732-183X
1527-7755
Alexandria
VA
2016 ASCO Annual Meeting
June 3-7, 2016
Chicago
United States
[en] oncology
http://hdl.handle.net/2268/199550

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with ... - abstract.pdfPublisher postprint724.28 kBRequest copy

Additional material(s):

File Commentary Size Access
Restricted access
Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with ... poster.pdf1.15 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.